What question did this study set out to answer?

The aim is to explore the use of secondary metabolites from Lobaria pulmonaria for treating multidrug-resistant tuberculosis.

February 19, 2026RSC Advances1 citationsOpen Access

Secondary metabolites from Lobaria pulmonaria (L.) Hoffm. target key metabolic enzymes: a novel strategy against multidrug-resistant tuberculosis

HNHa Thi NguyenDuy Tan University VBVishnu Nayak BadavathNarsee Monjee Institute of Management Studies SMSiddhartha MajiOklahoma State University

Key Points

The aim is to explore the use of secondary metabolites from Lobaria pulmonaria for treating multidrug-resistant tuberculosis.
Examined the traditional use of Lobaria pulmonaria in tuberculosis treatment.
Identified key metabolic enzymes targeted by secondary metabolites.
Investigated the efficacy of these metabolites against multidrug-resistant strains.
Secondary metabolites from Lobaria pulmonaria show potential in inhibiting key metabolic enzymes.
These findings highlight a novel strategy for combating multidrug-resistant tuberculosis.

Abstract

Numerous cultures have traditionally utilised the foliose lichen Lobaria pulmonaria (L.) Hoffm. (“Oak Lung” or “Lungs of Oak” in English; family: Lobariaceae) as a Tuberculosis (Tb) treatment.

Perguntar à IA

Bookmark

View Full Paper